Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the appointment of Chen Schor as a Board Director and Stephen Mitchener as Chief Business Officer. Schor, previously CEO of Adicet Bio, brings extensive leadership in biotech, aiming to enhance Karyopharm's growth in oncology. Mitchener, formerly with Axcella Healthcare, will leverage his experience in strategic finance and partnerships to expand Karyopharm's commercial reach. In connection with Mitchener's hiring, stock options were granted under Nasdaq rules, with a total of 159,000 shares allocated to newly hired employees.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that its Phase 3 SIENDO study of XPOVIO (selinexor) for advanced endometrial cancer passed a planned interim futility analysis. The Data and Safety Monitoring Board recommended continuing the study without protocol modifications. The study features 248 patients randomized to receive either XPOVIO or placebo, aiming to demonstrate a hazard ratio of 0.6 for progression-free survival. Top-line data is expected in the second half of 2021. XPOVIO has previously received FDA approvals for multiple myeloma and diffuse large B-cell lymphoma.
Karyopharm Therapeutics (KPTI) announced positive results from the Phase 3 SEAL study for XPOVIO® (selinexor) in treating advanced unresectable dedifferentiated liposarcoma at CTOS 2020. The study demonstrated a statistically significant increase in median progression-free survival (PFS) for patients treated with XPOVIO (2.83 months) compared to placebo (2.07 months, HR=0.70; p=0.023). XPOVIO also achieved a 30% reduced risk of disease progression or death. A New Drug Application to the FDA is anticipated in Q1 2021, marking XPOVIO as a potential first oral therapy for this cancer type.
Karyopharm Therapeutics (KPTI) announced results from the Phase 3 BOSTON study, published in The Lancet, which evaluated XPOVIO in combination with Velcade® and low-dose dexamethasone for relapsed or refractory multiple myeloma. The once-weekly regimen (SVd) showed a 30% reduction in disease progression or death risk compared to the standard regimen (Vd). Key metrics included a 47% improvement in progression-free survival and a 76.4% overall response rate. The FDA accepted a supplemental New Drug Application for XPOVIO with a PDUFA date of March 19, 2021.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, will have CEO Michael Kauffman participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 1:45 p.m. ET. Investors can access the live webcast on the company's investor site, with a replay available for 90 days after the event. Karyopharm specializes in novel drugs targeting nuclear export, notably XPOVIO® (selinexor), which received FDA approval for multiple myeloma and lymphoma. For more details, visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of twenty-one abstracts for virtual presentation at the ASH 2020 Annual Meeting, scheduled for December 5-8, 2020. Noteworthy presentations will include updated clinical data for XPOVIO (selinexor) in combination therapies for multiple myeloma and lymphoma. Key studies from the STOMP and BOSTON trials will be highlighted, showcasing encouraging response rates and safety profiles. An investor event will be held to discuss the clinical program and ASH data.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that the Compensation Committee granted stock options to purchase 86,900 shares to 13 new employees on October 30, 2020. The options have an exercise price of $14.82 per share, equivalent to Karyopharm's closing stock price on that date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly. Immediate full exercise is possible if employment is terminated for 'good reason' or without 'cause' within a year of a change in control event.
Karyopharm Therapeutics (KPTI) reported Q3 2020 financial results, achieving $21.3 million in net product sales, a 15% increase from Q2, primarily driven by new multiple myeloma and DLBCL patient starts. The company presented positive top-line results from the Phase 3 SEAL study, showing XPOVIO's efficacy in treating dedifferentiated liposarcoma, with plans to submit a New Drug Application to the FDA in Q1 2021. Karyopharm expects ongoing revenue from XPOVIO to support operations through mid-2022, despite a net loss of $53.5 million for the quarter.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive top-line results from the Phase 3 SEAL study, indicating that XPOVIO® (selinexor) significantly increases progression-free survival (PFS) in patients with advanced unresectable dedifferentiated liposarcoma, showing a 30% reduction in disease progression risk compared to placebo. The study involved approximately 285 patients, and results will be presented at the CTOS Annual Meeting on November 20, 2020. Karyopharm plans to submit a New Drug Application to the FDA in Q1 2021, potentially positioning XPOVIO as the first oral, non-chemotherapy treatment for this condition.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its third quarter 2020 financial results on November 2, 2020. A conference call led by the management team will take place at 4:30 p.m. ET that same day to discuss the results and company updates. The company focuses on developing innovative cancer therapies, including its lead product XPOVIO (selinexor), which has received FDA approvals for multiple myeloma and diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor is also under review in Europe.
